- Home
- RAND vs ESLA Comparison
RAND vs ESLA Comparison
Compare RAND & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAND | ESLA |
|---|---|---|
| Founded | 1969 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9M | 30.7M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | RAND | ESLA |
|---|---|---|
| Price | $10.38 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 1.8K | ★ 35.4K |
| Earning Date | 05-06-2026 | 05-26-2026 |
| Dividend Yield | ★ 10.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.00 | $0.69 |
| 52 Week High | $18.15 | $3.15 |
Technical Indicators
Market Signals| Indicator | RAND | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 37.43 |
| Support Level | $10.03 | $0.73 |
| Resistance Level | $10.49 | $1.35 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 100.00 | 23.56 |
Price Performance
Historical ComparisonAbout RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.